|1.||Renal Insufficiency (Renal Failure)
01/01/1987 - "Plasma 5-hydroxybendazac glucuronide accumulated according to the degree of renal insufficiency. "
01/01/1987 - "In patients with renal insufficiency urinary excretion of 5-hydroxybendazac was decreased and the systemic availability of the metabolite (AUC), was increased about three-fold, irrespective of the degree of renal failure. "
01/01/1987 - "Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency."
01/01/1987 - "The pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, have been investigated in 15 patients with moderate to severe renal insufficiency and renal failure following a single oral dose of 500 mg bendazac-lysine. "
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
01/01/1988 - "The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis."
01/01/1988 - "We have studied the pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, in 11 patients with hepatic cirrhosis after the oral administration of a single 500 mg tablet of bendazac-lysine, and compared them with those obtained from 10 healthy adults. "
|2.||bendazolic acid (bendazac)